Role Of Embolic Protection In Transcatheter Aortic Valve Replacement: Results From The Deflect I Study by Meller, Stephanie Michelle
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
January 2014
Role Of Embolic Protection In Transcatheter
Aortic Valve Replacement: Results From The
Deflect I Study
Stephanie Michelle Meller
Yale School of Medicine, stephanie.meller@yale.edu
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Meller, Stephanie Michelle, "Role Of Embolic Protection In Transcatheter Aortic Valve Replacement: Results From The Deflect I





ROLE OF EMBOLIC PROTECTION IN TRANSCATHETER AORTIC VALVE 





A Thesis Submitted to the  
Yale University School of Medicine  
in Partial Fulfillment of the Requirements for the  











Utilization of a cerebral protection device during transcatheter aortic valve replacement (TAVR) 
will reduce the rate of periprocedural stroke as well as the occurrence and volume of new lesions 
on diffusion weighted magnetic resonance imaging (DW-MRI), which may serve as a potential 
surrogate endpoint for clinical studies. The DEFLECT I study is a prospective, multi-center, 
single arm study that aims to demonstrate the safety and performance of the TriGard
TM
 Embolic 
Deflection Device (EDD) (Keystone Heart, Caesarea Business Park, Israel), among patients 
undergoing TAVR. Primary endpoints were device performance and in-hospital device-related 
safety.  A powered secondary endpoint was the number and volume of new DW-MRI brain 
lesions. Of the 20 consecutive patients enrolled, the device performed as intended with complete 
vessel coverage until completion of the valve implant in 80% of cases. The hierarchical 
composite in-hospital procedure-related major adverse cardiac and cerebrovascular (MACCE) 
event rates was 10% due to 2/20 major disabling strokes, which occurred the day after the 
procedure following urgent surgery for a failed TAVR implant and a cardiac arrest due to loss of 
pacer capture. Compared with historical controls, the number of new ischemic brain lesions 
detected on DW-MRI were similar (70% vs. 76%); however, patients undergoing TAVR with 
the TriGard
TM
 EDD device demonstrated a 94% reduction in the maximum lesion volume, a 
94% reduction in maximum total lesion volume, and a 65% reduction in mean lesion volume 
compared with historical controls. An angiographic sub-study demonstrated that the only clinical 
factor associated with the maintenance of device coverage throughout the procedure was 
anchorage of the upper stabilizer in the innominate artery. The DEFLECT I study established 
proof of concept of the TriGard
TM
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Transcatheter aortic valve replacement (TAVR) is increasingly used to treat patients with aortic 
stenosis deemed high or extreme surgical risk candidates. Since its introduction in 2002, clinical 
trials have proven its feasibility, safety, and efficacy.  Further, the randomized, controlled 
PARTNER trial demonstrated the superiority of TAVR to standard balloon valvuloplasty in 
patients at extreme risk and its non-inferiority compared with surgical aortic valve replacement 
(SAVR) in high surgical risk patients[1].  However, TAVR is not without its complications.  
 
Stroke has emerged as a major source of morbidity and mortality in patients undergoing the 
procedure[2, 3]. The periprocedural incidence of stroke has been estimated at 1.5% +/- 1.4%[2], 
but rates as high as 10% have been reported[4]. Stroke is also a known contributor to acute and 
ongoing mortality rates[5, 6]. 
 
In the following, we will define “stroke” and transient ischemic attack (TIA) according to the 
2012 VARC-2 definitions[7]. The pathogenesis of stroke or TIA associated with TAVR likely 
involves cerebral embolization during device positioning and implantation[5]. The nature of the 
TAVR procedure lends itself to catheter manipulation of the calcified aortic valve and 
atherosclerotic aorta.  Likewise, most studies show a consistent link between both TAVR and 
SAVR and embolic lesions visualized on diffusion-weighted-magnetic resonance imaging (DW-
MRI). Similar clinically silent lesions only identified with neuroimaging have been designated as 
“silent” strokes[8]. The question of whether these TAVR-related lesions lead to an increased risk 
of future cerebrovascular events with even longer term cognitive consequences remains open, 
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but given the large literature on silent strokes and cognition, this association is probable, with 
significant clinical implications. 
 
We will explore the likely significance of asymptomatic lesions seen on DW-MRI and present 
data supporting the link between silent stroke and cognitive decline in order to demonstrate the 
need for cerebral embolic protection during TAVR. Finally, we will discuss potential therapeutic 
options, including cerebral protection devices currently under investigation, to prevent stroke 
related to TAVR. 
 
Clinical Significance of DW-MRI Lesions 
DW-MRI detects changes in the self-diffusion of water molecules associated with ischemic 
injury[9].  In conjunction with the apparent diffusion coefficient, it is able to distinguish between 
cytotoxic edema caused by tissue infarction and vasogenic edema.  DW-MRI is highly sensitive 
for detecting brain ischemia, and widely available, making it a suitable method for detecting 
neurovascular events acutely following interventional procedures[10]. 
 
Early prospective studies investigating the risk of cerebral embolization associated with 
endovascular cardiac procedures, involving crossing of a stenotic aortic valve, demonstrated new 
post-procedure DW-MRI lesions in 2-22% of patients[11, 12]. A higher rate is expected with the 
bulkier devices utilized in balloon valvuloplasty and TAVR, and new foci of restricted diffusion 
on DW-MRI, consistent with embolic lesions (Fig. 1), have been demonstrated to occur in 68-
84% of TAVR patients, with more than 75% of patients enduring multiple new foci[9, 13, 14].  
The majority are asymptomatic with neurologic symptoms occurring in less than 10% of 
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Figure 1. Diffusion weighted-magnetic resonance images: (A) Baseline. (B) 
Following embolic event. Arrows indicate areas of restricted diffusion. 
 
patients[14, 15].  Though few studies have investigated their clinical significance in the context 





(Table 1).  
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those with new DW-MRI lesions following the surgery had significantly greater declines in 
cognitive function than those with stable MRI, evident as absolute changes in 
neuropsychological test performance.  In fact, the number of new DW-MRI lesions was 
correlated with the degree of overall decline as measured within 1 week following surgery[16].  
Barber et al. investigated the relationship between post-operative DW-MRI lesions and cognitive 
decline at 6 weeks, defined as a drop in the Reliable Change Index in at least 1 cognitive 
measure, following valvular surgery. They found that all patients with postoperative DW-MRI 
lesions had cognitive decline on at least 1 neuropsychological measure compared with only 35% 
of those without ischemic change[17].  
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In patients undergoing left heart cardiac catheterization, more than 16% of patients had post-
operative cognitive decline (POCD) following the procedure, defined as a drop of at least 20% 
on at least 2 of the 12 selected test variables, and patients with DW-MRI lesions failed to show 
improvement on repeat neuropsychological testing, as compared to those without such 
lesions[18].  The degree of cognitive decline was related to whether new lesions appeared on 
DW-MRI post-procedure.  In addition, Schwarz et al. compared neuropsychological outcomes in 
patients undergoing coronary catheterization and coronary artery bypass grafting up to 3 months 
following the procedure. Indeed, the presence of DW-MRI lesions correlated with POCD in 3 
cognitive domains when performed at 3 months as compared to baseline[19]. 
 
On the other hand, some studies suggest that DW-MRI lesions may be clinically irrelevant due to 
apparent reversability[13]. Importantly, DW-MRI lesion reversal may not indicate normalization.  
Animal studies have shown that even with DW-MRI hyperintensity reversal after ischemia, 
neurons exhibit structural damage and stress, and histological staining suggests that other non-
neuronal cell populations may compensate for the altered fluid balance seen on follow up 
imaging[20]. Alternatively, the lesions may simply drop below the sensitivity of standard DW-
MRI, as high field strength (3 Tesla) imaging has revealed significantly more lesions than 1.5 
Tesla studies[21].  
 
There is no data on the long-term consequences of DW-MRI lesions associated with TAVR, 
however extrapolation from the short-term studies noted above indicates that they cannot be 
dismissed. A number of studies have concluded that DW-MRI lesions are not predictive of long-
term POCD after cardiac surgery[22-24], but the limitations of these individual studies suggest 
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discrepancies in research methodology that should be improved (Table 1). The studies noted 
utilized 1.5 Tesla imaging, which may have failed to detect showers of small emboli and thus 
missed a potential association. In addition, the appropriate DW-MRI endpoint for cardiac 
procedures has not been defined and these studies reported various lesion characteristics, 
including mean lesion volume, maximum lesion volume, and number of lesions per patient, 
therefore increasing the difficulty of cross-study comparison.  
 
Importantly, the neuropsychological testing performed in these studies utilized batteries of 
multiple individual tests (Table 2).  The problem with using multiple individual tests selected at 
the investigator’s discretion is the variability of cognitive domains covered. TAVR-related DW-
MRI changes likely impact cognition in subtle ways and this association may be obscured if the 
cognitive domains most susceptible are not evaluated adequately and/or if neuropsychological 
instruments that are not sensitive to subtle injury are employed. Further, there is no standard 
definition for POCD associated with cardiac procedures, suggesting that determination of 
cognitive decline may vary between studies. There is also no standard neuropsychological 
battery for cardiac surgery and catheterization, including TAVR. The neuropsychological tests 
used have been proposed for the detection of vascular dementia, but the selection of tests that 
may be specific for this diagnosis might not be sensitive to cognitive change following the 
TAVR intervention[25].   
 
Thus, large, prospective studies with adequate follow-up would help to clarify the association of 
DW-MRI lesions with clinical outcome following cardiac catheterization procedures, especially 
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TAVR.  A standard neuropsychological battery for measuring cognition after cardiac procedures 
is also necessary. 
 
Silent Stroke and Cognitive Decline 
The relationship between stroke and cognition is well established[26, 27].  Silent stroke is also 
related to neurodegenerative and psychiatric diseases as well as decline in cognitive and motor 
abilities in the absence of frank dementia. The prevalence of silent strokes in the elderly 
population ranges between 13-21%[28, 29] and increases to 30-40% in patients older than 70 
years[30].  Although the association of DW-MRI lesions after TAVR with cognitive decline is 
under debate, there is a growing body of evidence linking silent strokes to poor cognitive 
outcomes and neurodegenerative diseases.  
 
A “silent” stroke is an area of infarction seen on neuroimaging in the absence of neurological 
signs or symptoms.  Blood flow in silent stroke is compromised and therefore results in neuronal 
damage, just as in symptomatic infarction.  Patients with silent stroke demonstrate “misery 
perfusion,” where there is a decrease in cortical blood flow with an increase in oxygen extraction 
fraction.  They also exhibit diaschisis in which subcortical silent stroke actually causes blood 
flow to decrease in the superior cortical areas[8]. 
 
Evidence for association between silent infarcts and cognitive dysfunction: 
The correlation between asymptomatic infarcts and cognitive impairment is convincing.  In a 
prospective study of 1015 elderly people, Vermeer et al. demonstrated that over a 5 year period, 
the presence of silent brain infarcts at baseline more than doubled the risk of dementia, with 
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Alzheimer’s Disease being the most common type (HR 2.26, 95% CI [1.09-4.70])[28]. The rate 
of new silent brain infarcts was higher in patients who developed dementia than in those who did 
not.  Further, the presence of silent strokes was associated with significantly worse global 
cognitive function as well as a steeper rate of cognitive decline.  Notably, the presence of 
multiple silent infarcts was more strongly correlated with cognitive decline than single 
infarcts[28]. Likewise, Blum et al. studied 658 community-dwelling elderly individuals who 
received MRI and found that those with any brain infarct had smaller hippocampi than those 
without. They also found that brain infarcts and smaller hippocampus volumes were 
independently associated with poorer memory, suggesting that a history of brain infarcts can 
contribute to a functional state similar to that of early Alzheimer’s Disease[31]. 
 
It is also known that symptomatic strokes contribute to poorer executive function in patients with 
Alzheimer’s Disease[32].  Similarly, Song et al. found that silent stroke was associated with 
increased severity of cognitive decline in patients with Alzheimer’s Disease[33].  An association 
between silent stroke and cognitive impairment, self-perceived health status, and independence 
in community dwelling elderly people has also been shown[29].   
 
In addition to cognition, silent strokes are also associated with depression and motor functional 
deficits. Fujikawa et al. observed the presence of silent stroke in 51.4% of patients with 
depression and in 93.7% of those with senile-onset depression[34].  Lastly, in a recent rat model, 
Faraji et al. demonstrated that repetitive focal ischemic mini-lesions to the sensorimotor cortex 
resulted in a decreased ability to accurately perform a walking task, indicating that concurrent 
silent strokes to the cortex can impair motor function[35].  
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Thus, the accumulation of silent strokes over time likely contributes to cognitive impairment and 
neurodegeneration.  Even 1 silent stroke puts people at risk for cognitive decline and 
dementia[28]. We suspect that such lesions lower the thresholds for future clinically significant 
strokes as well as the clinical expression of other neurodegenerative pathologies like Alzheimer’s 
Disease. In addition, silent strokes are associated with steeper cognitive decline in patients with 
diagnosed dementia.  Because TAVR-related microemboli often cause multiple new silent 
strokes that may contribute to the ischemic burden of the patient, the need for cerebral embolic 
protection is great.  
 
Embolic Protection in TAVR 
Cerebral embolic protection may be accomplished through drugs, such as anti-platelet or 
antithrombotic regimens, and devices, including capture or deflective devices. 
 
Anti-thrombotic regimens: 
The literature is scarce regarding the appropriate anti-thrombotic regimen for TAVR. The only 
randomized trial to date evaluated the need for dual anti-platelet therapy with aspirin and 
clopidogrel for 3-6 months after the procedure in 79 patients and found no clinical benefit from 
the addition of clopidogrel[36].  This finding is important because patients with chronic atrial 
fibrillation treated with warfarin and aspirin demonstrate a significantly increased bleeding risk 
with the addition of clopidogrel for catheterization procedures[37]. Larger, prospective studies 
would be helpful in assessing the need for and type of antithrombotic therapy for patients 
undergoing TAVR. 
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Cerebral protection devices: 
Given the temporal pattern and arterial distribution of the majority of TAVR-related infarcts[5], 
peri-procedural cerebral embolization is the most likely mechanism of cerebral infarction. 
Therefore, anti-thrombotic regimens are unlikely to provide as much benefit as filter-based 
protection devices, the utility of which has been demonstrated in carotid artery stenting. There 
are a few devices that have been developed specifically for cerebral protection in TAVR.  These 
include the Claret CE Pro
TM
, the Embrella (Edwards Lifesciences, Irvine, CA, USA) deflection 
system, and the TriGard
TM
 embolic DEFLECTion device (EDD) (Keystone Heart Ltd., Herzliya, 
Israel), which vary in their delivery sheath sizes, routes of delivery, and vessel coverage (Table 
3). 
 
The Claret CE Pro
TM
 (Fig. 2) is the only device that captures and removes debris from the body. 
The device uses a 6F transradial or brachial delivery system, a 9-15 mm brachiocephalic artery 
filter, and a 7-10 mm left common carotid artery filter, with 140-micron pore sizes[38]. The first-
in-man trial in 35 patients 
demonstrated first-generation 
device and second-generation 
device success rates of 60% 
and 87%, respectively.  Debris 
was captured in 54.3% of 
patients and no procedural 
cerebrovascular events 
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Figure 3. Embrella embolic deflector. 
 
occurred; however 1 patient experienced a minor stroke and 2 patients suffered major strokes 
within 30 days of the procedure; 1 major stroke occurred within 4 hours of the procedure[38].  
This study was limited by the absence of pre- and post-procedural neuroimaging as well as tests 
of neurocognitive function. 
 
Like the Claret CE Pro
TM
, the 
Embrella (Fig. 3) only covers 
the innominate and left carotid 
arteries, but may also cover the 
left subclavian artery up to 60% 
of the time. The device also 
uses a 6F transradial or brachial 
delivery system. It consists of 
100 micrometer sized pores on 
a membrane mounted on a 
Nitinol frame and shaft, with 3 radiopaque markers to aid fluoroscopy-guided delivery.  The 
first-in-human study successfully employed the device in 4 patients without damage to the 
arteries or interference with the TAVR procedure.  None of the TAVR patients exhibited new 
periprocedural neurologic symptoms or new findings on pre-discharge MRI, however one patient 
who underwent balloon valvuloplasty alone demonstrated a new 5-mm acute cortical infarct in 
the right temporal lobe[39].  
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Figure 4. Keystone Heart Triguard
TM




 EDD (Fig. 4) covers all 3 cerebral inflow vessels and is delivered via the 
transfemoral route.  It uses a larger delivery catheter (9F) via the contralateral transfemoral 
approach, and a heparin-
coated Nitinol mesh to 
deflect embolic debris. A 
vertical stabilizer is 
positioned in the innominate 
artery and lower feelers 
anchor the device against the 
upper wall of the aortic arch.  
It is the only system that 
covers all 3 of the great 
vessels branching off of the aorta, providing the maximal scope of protection[40].  A pilot study 
of 15 patients demonstrated device safety, and significant reduction in embolic events (average 
of 3.2 new DW-MRI lesions per patient vs. 7.2 per historical)[40].  The only neurological 
complication involved 1 patient suffering a TIA within 2 days of the procedure. A 60 patient CE 
mark trial is currently underway with formal DW-MRI and neuropsychological assessment. 
 
Embolic protection devices show promise in decreasing the rate of cerebral embolization and 
stroke in patients undergoing TAVR but their ability to prevent or decrease the long-term 
occurrence of stroke is unclear. Likewise, cerebral infarction due to procedural hypotension as 
well as continued embolization from the calcific, degenerated native valve cusps and valve 
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prosthesis would not be affected by the use of procedural deflection devices. These issues remain 
to be addressed with further refinement of TAVR. 
 
Neuro-Imaging as an Endpoint Measure 
Choosing an appropriate endpoint for a clinical trial can be complex. In fact, up to 10-15% of 
medical devices that enter the EU regulatory pathway lack relevant endpoints, which is 
considered grounds for objection.  The penetration rate of devices in general, and in TAVR 
specifically, is significantly delayed in the US compared to Europe mostly due to FDA 
requirements for reasonable assurance of safety and effectiveness of a device prior to its approval 
[40].  
 
For clinical trials investigating neuro-protection devices for use in cardiac procedures, the 
investigators must prove that the device is able to reduce the occurrence and/or severity of 
cerebral events. Ideally this would be accomplished by reporting an actual reduction in the rate 
of stroke, transient ischemic attack, and other neurologic events according to Valve Academic 
Research Consortium-2 definitions [7]. Because the occurrence of TAVR-related stroke is 
relatively low (<10%), a large sample size would be needed to detect a difference in clinical 
event rate with versus without a protection device. In addition to sample size requirements, the 
rising cost of clinical trials limits the feasibility of using relatively uncommon clinical events as 
trial efficacy endpoints. Further, silent ischemia accounts for the majority of lesions detected on 
neuro-imaging following TAVR procedures. Using a clinical event endpoint to measure device 
success would miss the occurrence of these silent lesions, which are associated with cognitive 
decline and mortality [41, 42]. 
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Neuro-imaging, specifically DW-MRI, may serve as a surrogate endpoint for clinical studies 
detecting cerebral events in which cost and sample size limitations prohibit the use of clinical 
outcomes. DW-MRI, which has sensitivity and specificity up to 92% and 97%, respectively, 
combines features of conventional spin echo and gradient echo techniques to image the freedom 
of the diffusion of water molecules to identify restriction in diffusion, suggestive of cerebral 
ischemia [43]. In cytotoxic edema due to hypoxia, the re-distribution of water from the 
extracellular to the intracellular space is visible within zero to five days of the event (Fig. 1). On 
DW-MRI, normal tissue appears gray due to the Brownian motion and diffusion of water 
molecules, whereas restricted diffusion in the case of ischemia prevents the normal loss of MRI 
signal and thus appears white. A bright signal on DW-MRI and a dark signal on the 
corresponding apparent diffusion coefficient map is characteristic of acute brain injury within 
five days. 
 
One important issue to consider is that evidence for long-term consequences of lesions detected 
by DW-MRI is lacking. Indeed, recent studies have implied that DW-MRI lesions after TAVR 
are not related to self-sufficiency or mortality one-year post-procedure and that there may even 
be less cognitive decline post-TAVR compared with surgery, despite a higher incidence of 
embolic lesions [44, 45]. These studies are limited by small sample sizes but they suggest that 
there may limitations in utilizing DW-MRI to evaluate TAVR outcomes. 
 
Another major limitation of using DW-MRI in clinical trials is that no clear definition of the 
endpoint exists. Qualitative measurements include lesion number and vascular territory involved 
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and quantitative measurements include total lesion volume, average lesion volume, and 
maximum lesion volume. All are key neuro-imaging endpoint parameters to follow the efficacy 
of neuro-protection, however, the endpoint must be standardized to allow for cross-study 
comparison. 
 
Ongoing clinical trials investigating cerebral protection devices for TAVR are utilizing various 
DW-MRI measures to determine device efficacy. The ongoing Prospective Randomized 
Outcome Study in Patients Undergoing TAVR to Examine Cerebral Ischemia and Bleeding 
Complications (PROTAVI) trial, which is randomizing patients eligible for TAVR to undergo 
the procedure with or without the Embrella deflection device, will analyze the rate of new DW-
MRI brain lesions at seven days post-procedure. Likewise, the DEFLECT I trial is a single arm 
study enrolling up to 60 patients in the EU, Canada, and Brazil to undergo TAVR with the 
Keystone Heart Trigard
TM 
in place using the presence of new DW-MRI lesions post-procedure 
compared with a historical control group as a measure of device success. 
 
Although DW-MRI lesion presence and rate of occurrence are being used as endpoints, total 
lesion volume is the most reproducible measurement when performed in an experienced core 
laboratory, and along with geographic location, provides the best measure of overall burden of 
ischemic injury, and may therefore be a more appropriate endpoint measure. Though it fails to 
identify the functional region of the brain involved, studies have identified DW-MRI lesion 
volume as an independent predictor of clinical outcome after acute stroke [46, 47]. Specifically, 
mean lesion volume has been correlated with mental changes and vascular dementia following 
endovascular procedures [48]. In contrast, the presence and number of DW-MRI lesions are only 
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likely to be clinically relevant if the individual lesion is large or in an area of functional 
significance [49]. Therefore, the Yale-University College of London (UCL) summit concluded 
that DW-MRI lesion volume should be measured by independent core laboratory assessment 
with validated and reproducible methodology and should be included and reported in all clinical 
studies using DW-MRI to investigate neuro-protection devices for use in TAVR. We recommend 
that single lesion volume, number of new ischemic lesions, and total lesion volume be measured. 
 
Lastly, in 2011, the FDA issued draft guidance for clinical trial imaging endpoints for studies 
intending to confirm drug efficacy, recognizing that the use of imaging may assist in the 
assessment of safety and efficacy as well as patient eligibility. US regulatory requirements have 
been an impediment to early clinical testing of new devices, which US investigators have mostly 
out-sourced overseas.  During the Yale-UCL summit, the FDA expressed its goals to encourage 
medical device innovation, enhance regulatory science, and facilitate early feasibility clinical 
studies in the US. Consensus from the 2013 Yale-UCL summit called for validation of imaging 
endpoints in neuro-protection trials involving medical devices and encouraged European 
regulatory bodies and the FDA to work with the clinical and device industry to support this 
position [50]. 
 
In summation, filter-based embolic protection devices, the utility of which has been 
demonstrated in carotid artery stenting, show promise as a means of preventing stroke and other 
neurologic complications following TAVR.  Prevention of neurological complications is 
necessary in order to fully realize the potential of TAVR and optimize the outcomes of patients 
with severe aortic stenosis. Mean and total lesion volume, as measured on DW-MRI, may be 
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appropriate surrogate endpoints for clinical studies like DEFLECT I. We report the results of the 







Patients undergoing TAVR with the Keystone Heart TriGard
TM 
EDD in place will demonstrate a 
lower rate of periprocedural stroke, as well as a reduction in the number and volume of new 
brain lesions on DW-MRI. 
 
SPECIFIC AIMS 
1. To evaluate the safety and performance of the Keystone Heart TriGardTM EDD in patients 
undergoing TAVR 
2. To determine the risk of clinical stroke with the EDD in place. 
3. To evaluate the occurrence and size of new DW-MRI brain lesions with the EDD in place 
as compared with historical controls. 
4. To evaluate the impact of baseline cardiac anatomy and procedural characteristics on 




Study Design and patient population 
The DEFLECT 1 clinical trial is a prospective, multi-center, single arm study, designed to 
evaluate the safety and performance of the TriGard
TM
 EDD in patients undergoing TAVR for the 
purpose of obtaining European Union (CE Mark) approval on the basis of 20 consecutive 
patients, but allowing extended enrollment of up to 60 patients from up to 10 investigational sites 
in the European Union, Brazil and Canada.  
 
Patients were included if they were older than 18 years of age, met current indications for 
TAVR, and were willing to comply with protocol-specified follow-up evaluations.  Patients were 
excluded from the study if they were undergoing TAVR via the trans-axillary, subclavian, or 
direct aortic route, were in cardiogenic shock, or had a known myocardial infarction (MI) within 
72 hours of the procedure, had impaired renal function (Glomerular Filtration Rate <30); 
bleeding diathesis, coagulopathy, or refusal of blood transfusion, past or pending organ 
transplantation, known medical illness or history of substance abuse that could interfere with 
compliance, stroke, TIA, known hypersensitivity or contraindication to aspirin, heparin/ 
bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or contrast sensitivity that 
could not be adequately pre-medicated, severe peripheral arterial disease precluding delivery 
sheath vascular access, documented friable or mobile atherosclerotic plaque in the aortic arch, 
contraindication to cerebral DW-MRI, or had planned treatment with any other investigational 
device or procedure during the study period. Patients meeting eligibility criteria for TAVR were 
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Figure 5. Angiography demonstrating Keystone Heart Triguard
TM
 device position. (A) Before the TAVR 
procedure. White arrow indicates device upper stabilizer anchorage in innominate artery. (B) During the 
TAVR procedure. (C) After the TAVR procedure. TAVR, transcatheter aortic valve replacement. 
enrolled in the study after providing written informed consent. A medical ethics committee/ 





 EDD (Fig. 4) is intended to be delivered percutaneously via a 9 Fr sheath and 
positioned in the aortic arch to deflect and reduce embolic material (debris/ thrombus) to the 
cerebral arteries during endovascular procedures. It is a temporary single use, biocompatible 
filter, made of fine nitinol #1 (nickel titanium alloy) wires, which is anchored in position by an 
atraumatic stabilizer, positioned in the ostium of the innominate artery (Fig. 5). The filter portion 
of the device covers all three major cerebral arteries in the aortic arch (innominate, left common 
carotid and subclavian) and maintains blood flow to the cerebral vessels through 250 m sized 
pores, while deflecting larger embolic/particulate matter toward the descending aorta. The filter 
is coated with an antithrombotic coating (Applause™ Heparin Coating, Surmodics, USA).  
20 20 
 
Screening and Procedure Description 
 A series of routine tests were performed to assess general patient eligibility for the study 
including cardiac biomarkers (CK, CK-MB isoenzyme and troponins) within 24 hours of the 
procedure to exclude MI and a baseline computed tomography angiogram (CTA) of the left 
heart, aortic arch and great vessels extending to the peripheral access vessels per standard of 
care. Patients meeting eligibility criteria signed informed consent prior to enrollment in the 
study.  DW-MRI of the brain was performed within 21 days prior to the procedure.  
Comprehensive neurological assessments were performed at baseline, including the NIH Stroke 
Scale, the Modified Rankin Scale and the Montreal Cognitive Assessment (MoCA).[51] These 
were performed within one week of the procedure by a trained and qualified individual, and 
repeated by a neurologist or neurology fellow when a stroke or TIA was suspected. 
All patients were treated with a 300-325 mg loading dose of aspirin and 75-325 mg of aspirin 
prior to the procedure, and either 300 mg of clopidogrel 6 hours before the procedure or 600 mg 
peri-procedurally. Following the procedure, the recommended antiplatelet regimen was ASA 75 
mg daily indefinitely and 75 mg daily of clopidogrel for at least 6 months. 
 
TAVR was performed according to standard institutional practice under local or general 
anesthesia using a transapical or transfemoral approach as indicated.  At the start of the 
procedure, a 9Fr arterial sheath was inserted in the contralateral femoral artery, the EDD device 
was advanced and deployed across the aortic arch, covering the ostia of the 3 major neck vessels 
(innominate, left common carotid and subclavian) and withdrawn at the completion of the TAVR 
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procedure. The procedure was complete once the guiding catheter was removed from the patient 
and the patient was off the table. 
 
Clinical Follow-up 
Follow-up DW-MRI of the brain was performed at 42 days (range 2-6 days) post-procedure.  A 
one-month clinical follow-up visit was scheduled for 307 days post-procedure for anginal status 
(Canadian Cardiovascular Society, Braunwald or silent ischemia) and any adverse events. A 
neurologic evaluation consisting of the NIH Stroke Scale, Modified Rankin Scale, and MoCA, 
was performed at discharge and 1 month follow-up by an independent qualified individual and 
repeated by a neurologist or neurology fellow if a stroke or TIA was suspected.  
 
Endpoints and Definitions 
Primary Endpoints   
The study had two primary endpoints:  The primary device performance endpoint was defined as 
the ability to (1) access the aortic arch with the delivery catheter, (2) deploy the EDD, (3) 
position the device to cover all 3 cerebral inflow vessels (verified by angiography) without 
obstruction of blood flow or interference during the TAVR procedure, and (4) retrieve the EDD 
device and delivery system, in the absence of adjudicated device malfunction (Fig. 5).   Device 




The primary safety endpoint was in-hospital device and procedure-related safety, defined as the 
incidence of investigational device and investigational procedure-related serious adverse events 
in a composite hierarchical safety endpoint. The components of this safety endpoint included: 
Valve Academic Research Consortium (VARC) defined as (1) cardiovascular mortality, (2) 
major stroke disability, (3) life-threatening or disabling bleeding[52], (4) distal embolization 
(noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible 
end organ damage, major vascular or access-related complications and (5) need for acute 
cardiovascular surgery (defined as immediate transfer from the catheterization lab to the 
operative room during the initial treatment phase due to the need for emergency coronary artery 
bypass graft surgery, cardiac valve surgery, or other vascular surgical intervention).   
Secondary Endpoints  
A major powered secondary efficacy endpoint was the number and volume of new embolic 
lesions detected by DW-MRI of the brain from pre-procedure to 4±2 days (range 2-6 days) post-
procedure compared to a historical control (Table 3).  
Additional secondary performance endpoints included: (1) procedure success, defined as 
successful device performance without the occurrence of the primary composite safety endpoint 
(defined above); (2) device deployment time (defined as the time elapsed between insertion of 
the EDD into the delivery sheath and successful deployment into the aortic arch); and (3) total 
procedural time (defined as the time elapsed between the first arterial access and removal of the 
last guiding catheter from the arterial access sheath). 
 
Other secondary safety endpoints were measured in hospital and at 30 days and included: (1) 
device-related safety (component and hierarchical composite), as defined above for the primary 
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safety endpoint, (2) Major Adverse Cardiac and Cerebrovascular Events (MACCE) defined by a 
hierarchical composite endpoint of VARC-defined all-cause mortality, major stroke disability, 
life-threatening (or disabling) bleeding, acute kidney injury – stage 3, peri-procedural MI, major 
vascular complication, and repeat procedure for valve-related dysfunction[52]; (3) VARC-
defined all cause and cardiovascular mortality, periprocedural and spontaneous MI, major and 
minor vascular complications, acute kidney injury, and neurological events (both component and 
composite), including stroke and its sub-classifications[52], as well as cerebral infarction 
(defined as evidence of brain cell death from imaging studies or pathological examination), 
encephalopathy (defined as altered mental state, e.g., seizures, delirium, confusion, 
hallucinations), and intracranial hemorrhage (defined as a collection of blood between the brain 
and skull, subcategorized as epidural, subdural, and subarachnoid bleeds), and cognitive 
dysfunction as assessed by the MoCA.  
 
Study Conduct and Central Laboratories 
Site monitoring was performed for 100% of clinical fields and clinical events (MedPass 
International, Paris, France).  All adverse events were adjudicated by an independent Clinical 
Events Committee (Yale Cardiovascular Research Group, New Haven, CT) and all neurologic 
evaluations including NIH Stroke Scale, Modified Rankin Scale and MoCA were independently 
reviewed by an expert neurologist (AB, Columbia University, New York, NY). Three 




Angiographic Core Laboratory (Yale Cardiovascular Research Group, Yale University, New 
Haven, CT): All procedural angiograms were sent and reviewed independently by qualified 
analysts trained in the procedure, the investigational device and its intended use. The 
angiographic analysis included the first consecutive 20 patients enrolled in the trial. An 
independent angiographic core laboratory performed comprehensive quantitative coronary 
angiography of baseline and final angiograms using validated methods (Medis, Leiden, The 
Netherlands). All EDD performance criteria including successful 1) access of the aortic arch with 
the delivery catheter, (2) deployment of the EDD, (3) positioning of the device to cover all 3 
cerebral inflow vessels without obstruction of blood flow or interference with the TAVR 
procedure, and (4) removal of the device, were adjudicated by the core laboratory and used for 
reporting of the primary endpoint. Further angiographic analysis consisted of determining, 
before, during, and after the TAVR procedure, whether the EDD covered all 3 aortic arch 
vessels, whether the EDD upper stabilizer was anchored in the innominate artery ostium, and the 
aortic arch classification. In addition, the innominate artery reference vessel diameter (RVD), 
take off angle from the innominate artery and aortic arch, take off angle from the EDD after 
positioning in the aortic arch, and take off angle from the EDD after TAVR were measured.  All 
cases were reviewed for quality control by the laboratory director. 
 
Diffusion-Weighted MRI Core Laboratory (Global Research Institute, Richmond, VA): All 
baseline and follow-up DW-MRI images were reviewed and analyzed by an independent core 
laboratory.  The analysis was performed blinded to temporal sequence, using validated 
qualitative and quantitative methods (Vitrea, Version 6.3.2; Olea, NeuroScape; Version 1.2.0). 
Axial DW-MRI images and corresponding apparent diffusion coefficient (ADC) maps, as well as 
25 25 
corresponding T2-weighted images were reviewed for the presence of lesions with high signal 
intensity on DW-MRI. Acute ischemic lesions were defined as those areas of high signal 
intensity on DW-MRI with corresponding areas of low signal intensity on the ADC maps. 
Corresponding T2-weighted images were also reviewed for T2-shine through. Coronal and 
sagittal image reformats were also reviewed to determine whether lesions were single or 
multiple. For each patient, the total number of lesions on the pre-TAVR DW-MRI, the total 
number of lesions on post-TAVR DW-MRI, and the total number of new lesions were recorded. 
For each positive lesion on DW-MRI, the number of positive voxels, as measured with the Olea 
software, and the volume of each lesion were recorded. Lesion volumes were summed across 
each patient to yield total lesion volume. 
 
CT Angiography Core Laboratory (Global Research Institute, Richmond, VA):  All pre-
procedural CTAs were forwarded to an independent CT angiographic core laboratory to perform 
independent assessment of anatomic measures potentially related to device performance and 
cerebral embolization including vessel tortuosity, presence and extent of valve and vascular 
calcification and plaque among others.  All quantitative measures were performed using 
validated software (Medis, Leiden, The Netherlands). 
 
Statistical Analysis 
The intent to treat population is the primary analysis population for DEFLECT I. Continuous 
variables are presented as mean  standard deviation (SD). Binary variables are described as 
frequencies and percentages. The hypothesis of the powered secondary efficacy endpoint is that 
the EDD will be superior to the historic control with respect to the number and volume of new 
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embolic lesions detected by DW-MRI of the brain from pre- to post-procedure. The historic 
control for new cerebral lesions was derived from a weighted average of 5 clinical trials (Table 
1)[9, 13, 15, 53, 54]. These trials were chosen due to similar inclusion/exclusion criteria and 
similar time points for DW-MRI follow-up. Thus, the control event rate based on contemporary 
data is assumed to be 76%. The sample size is calculated for the hypothesis of superiority 
assuming 90% power to detect a 40% reduction in DW-MRI lesions with the EDD.  With a two-
sided α=0.05, a minimum total of 28 patients treated with the EDD would provide 90% power to 
conclude that the EDD was superior to historical controls without neuro-protection. The protocol 
allows continued enrollment of up to 60 patients to account for loss to follow-up or 
contraindication to a post-procedure DW-MRI (e.g., pacemaker implantation) to meet the 
efficacy endpoint.  For the angiographic sub-study, all statistical analyses were performed using 
SAS version 8.2 (SAS Institute Inc, Cary, North Carolina). Categorical variables are presented as 
frequencies and were compared with Pearson chi-square or Fischer’s exact test. Continuous 




I participated in protocol development and revision, as well as weekly teleconferences with the 
trial sponsor and monitor. Patient enrollment and data collection were performed by individual 
investigators at the international sites. I led the clinical events committee, which served to 
adjudicate all adverse events. My responsibilities for that role included obtaining source 
documents from the international sites, writing detailed narratives for each adverse event and 
angiographic analysis, preparing adverse event and adjudication forms, as well as recruiting a 
diverse panel of 4 clinical experts from Yale to adjudicate each event. I also assisted with 
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presentation preparation for the sponsor meetings, performed interim and periodic statistical 
analyses, drafted the manuscript for publication and am currently participating in revisions. For 
the angiographic sub-study, I designed the study, collected all of the data, performed the 
statistical analyses in SAS, wrote the abstract, and gave the oral presentation at EuroPCR. 
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RESULTS 
A total of 20 patients were enrolled in DEFLECT I from 5 actively participating clinical EU 
sites, including 8 patients from University College of London Hospitals, 2 patients from 
University Hospitals of Leicester, 2 patients from Brighton and Sussex University Hospital, 7 
patients from University Hospitals of Bristol, and 1 patient from Amphia Ziekenhuls 
Molengracht Breda.  The study population is representative of subjects undergoing TAVR with 
high or extreme risk indications (Table 4).  A total of 21 valves were implanted in 20 patients 
through the transfemoral approach with general anesthesia in 90.0% (18/20); 47.6% (10/21) 
recieved the Edwards SAPIEN heart-valve system (Edwards Lifesciences, USA) and 52.4% 
(11/21) the Medtronic CoreValve® system (Medtronic, Inc., USA). Pre-TAVR balloon 
valvuloplasty was performed in 16/20 (80%) cases.  TAVR implantation was successful in 19 
out of 20 cases.  A single case required urgent conversion to surgical aortic valve replacement 
after failed implantation of 2 TAVR devices complicated by severe aortic insufficiency.  
 
Primary endpoints 
A total of 21 EDD devices were successfully delivered to the aortic arch in 20 patients (100% 
delivery success).  The EDD and delivery sheath accessed the aortic arch, deployed into the 
aortic arch and were retrieved intact in 100.0% (21/21) of devices used. Coverage of all three 
cerebral vessels was achieved in 95.0% (19/20) of cases prior to the TAVR procedure; in 1 case, 
2 devices were attempted but the investigator was unable to successfully position the device as 
intended due to poor visualization in an obese patient. 
 
The EDD device performed as intended in 80.0% (16/20) of cases with complete cerebral vessel 
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coverage from initial EDD positioning, passage of the TAVR delivery system, and positioning 
and deployment of the TAVR device.   The EDD remained in position with full coverage of all 
cerebral vessels until after removal of the TAVR delivery system in 65.0% (13/20) of cases. 
Device performance results are reported in Table 5.  
 
The primary safety endpoint of in-hospital EDD and procedure related safety was not met by any 
patient (0%) as there were no EDD adjudicated device or procedure related cardiovascular 
deaths, major stroke disability, life-threatening (or disabling) bleeding, distal embolization, 
major vascular/access site related complications or the need for acute cardiovascular surgery 
reported (Table 6). 
 
Secondary Endpoints 
Procedure success was 80%, mean device deployment time was 16.413.8 minutes, and mean 
total procedure time was 85.615.9 minutes.  There was no obstruction to cerebral blood flow or 
interference of the EDD with the valvuloplasty or TAVR procedure reported in any of the cases.  
 
The composite (non-EDD related) in-hospital MACCE was 10% as a result of 2  major stroke 
disabilities.  One stroke occured the day following urgent surgical conversion after a failed 
TAVR implant, and the second stroke occured in a patient whose procedure was complicated by 
loss of ventricular capture from a temporary pacing lead in the setting of complete heart block, 
requiring cardiopulmonary resuscitation.  There was one major vascular complication (5.0%); a 
thoracic aortic dissection occurring in the same patient who underwent 2 failed TAVR attempts 
with urgent conversion to surgery. The dissection was diagnosed intra-operatively following 
30 30 
manual manipulation of the TAVR device and removal. It was repaired surgically and the patient 
recovered.  There were 2 patients (10.0%) who experienced AKI (stage 1 (n=1), stage 3 (n=1)) 
related to contrast administration during the study procedure. There were a total of 4 non-EDD 
related major bleeding events (20.0%), all of which resulted in a drop in hematocrit >15% and 5 
minor vascular complications (25.0%), 3 of which (left groin hematoma, bilateral groin 
hematomas, and bilateral femoral access site oozing) involved the EDD delivery system.  All 
bleeding complications resolved without sequelae.  
 
At 30 days the hierarchical MACCE was 15%; in addition to the 2 in-hospital major stroke 
disabilities, there was an additional non-cardiovascular death in a patient who developed 
broncho-pneumonia that occurred after discharge but prior to 30-day follow-up. Primary and 
secondary safety endpoints are summarized in Table 6. 
 
DW-MRI 
DW-MRI results are presented in Table 7. No patients were excluded due to unobtainable or un-
interpretable DW-MRI images. New post-procedure DW-MRI lesions were found in 70% 
(14/20) patients. This rate was not significantly different than the weighted mean of historical 
control rates from studies reported in unprotected TAVR (70% vs. 76%)[9, 13, 15, 45, 53-55]; 
however, there was a 94% reduction in maximum single lesion volume (0.39 vs. 6.45 cm
3
),[15, 
45] a 65% reduction in mean single lesion volume (0.12 vs. 0.34 cm
3
),[13, 15, 45, 54, 55] a 57% 
reduction in mean total lesion volume (0.7 vs. 1.64 cm
3
),[13, 15, 45, 54, 55] and a 94% reduction 






100% of patient angiograms were suitable for complete analysis.  7 patients were classified as 
aortic arch type I (35%), 9 type II (45%), and 4 type III (20%). Anatomical measurements, 
presented as mean +/- standard deviation, are as follows: innominate artery RVD (11.49 +/- 
1.54), take off angle from innominate artery and aortic arch (73.52 +/- 26.19), take off angle 
from EDD after positioning (114.72 +/- 30.35), and take off angle from EDD after TAVR 
(120.28 +/- 26.95). The only angiographic characteristic significantly associated with complete 
device coverage before, during, and after the TAVR procedure was whether the device upper 
stabilizer was anchored in the innominate artery at those respective time points (Prior: p = 0.01; 
During: p = <0.0001; After: p = <0.0001). No baseline anatomical characteristics were 
associated with the ability of the device to maintain coverage (Table 8). 
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DISCUSSION 
Peri-procedural stroke is a significant contributor to morbidity and mortality in high-risk patients 
undergoing TAVR. Recent studies have demonstrated an early high-peaking hazard phase in the 
period immediately following the procedure as well as an arterial distribution of periprocedural 
cerebral infarcts reflective of typical embolic patterns[5, 56]. These data support embolization of 
atherosclerotic debris during valve implantation and balloon aortic valvuloplasty as the most 
likely mechanism for periprocedural stroke in TAVR, and provides the rationale for neuro-
protection during the TAVR implant procedure.  Neuro protection is not intended to completely 
eliminate the risk of clinical stroke or neuro embolic events. Though approximately 50-65% of 
all strokes occur during the procedure, an increased stroke risk is present in the months following 
the procedure and is likely related to the high-risk profile of the patient population and 
potentially thrombosis of the implanted valve.[57-59] 
 
The DEFLECT study provides evidence for the feasibility, performance and preliminary efficacy 
of the TriGard
TM
 EDD.  The EDD was placed in the aortic arch and successfully retrieved in all 
cases, with proper positioning and protection of all cerebral vessels until completion of TAVR in 
80% of cases.  Thus, in the majority of cases the device was properly positioned to provide 
neuroprotection during balloon valuvloplasty and valve prosthesis deployment, the period during 
which the majority of cerebral embolic events have been demonstrated to occur[60, 61]. The 
EDD was maintained in position until complete retrieval of the TAVR delivery system in 65% of 
cases. Whether there is incremental benefit in retaining complete neuroprotection until complete 
removal of the TAVR system remains to be seen.  Several studies using TCD have shown that 
the majority of microembolization occurs during balloon valvuloplasty and TAVR prosthesis 
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positioning and deployment and not during the retrieval phase of the TAVR delivery system.[60, 
61]  TCD data gathered throughout the TAVR procedure during each DEFLECT case, will help 
further clarify the precise period during which the EDD must be in place to provide optimal 
protection. 
 
It is important to note that most device performance failures (inability to position the EDD and 
maintain its position) occurred in the first 1-2 cases at the investigational sites. As with any novel 
device, a learning curve is expected and we did see placement improvement in later cases. We 
predict further improvement in overall device performance with additional enrollment.  
 
Though the proportion of patients with new ischemic lesions, and the maximum and average 
number of new lesions were similar in DEFLECT-I as compared with historical controls, 
maximum and mean single lesion volume were much smaller than the respective averages in the 
reported literature. Overall, total lesion volume was smaller in DEFLECT-I, which was primarily 
driven by the reduction in the single lesion volume. These results suggest that the Triguard
TM
 
EDD device was successful in deflecting larger emboli away from the cerebral vessels, resulting 
in significant reductions (up to 94%) in maximum single lesion volume. Similarly, mean lesion 
volume was 65% lower compared to historical controls. While overall lesion numbers were 
slightly higher compared to historical data, due to lower single lesion volume, maximum total 
lesion volume on a per-patient basis was 18-fold smaller compared to the one study in the 
reported literature, representing a 94% reduction in maximum total lesion volume.  
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While 2 disabling strokes occurred, they occurred after TAVR and in association with urgent 
surgical conversion of the failed TAVR procedure in the first case and following cardiac 
resuscitation in the second case.   
 
It is unlikely that these strokes reflect a failure of neuro-protection.  Major stroke event rates 
reported in similar trials range from 3.8%[62] to 5.0%[1] up to 30 days. We would not expect 
complete elimination of neurologic events in our study; however, use of the Keystone Heart 
TriGard
TM
 should result in a decreased peri-procedural stroke rate associated with uncomplicated 
TAVR as well as a reduction in silent ischemic events. While symptomatic strokes can result in 
obvious disability, multiple studies have demonstrated the cognitive implications of DW-MRI 
lesions in cardiac procedures.[16, 17, 41] Further, DW-MRI lesion volume may be a more 
valuable measure than number of lesions because volume is most indicative of overall ischemic 
burden and is predictive of clinical outcome after stroke.[46, 47] Following endovascular 
procedures, mean lesion volume has been associated with vascular dementia and cognitive 
changes.[48] Thus, the Keystone Heart EDD resulted in large relative reductions in single and 
total lesion volumes compared with historical controls, suggesting that device utilization can 
result decreased overall ischemic burden and post-operative cognitive changes. Neurocognitive 
testing results will lend further support to this finding; however, a randomized trial comparing 
protected vs. unprotected TAVR is necessary.     
 
Performance of the TriGard
TM
 EDD in this early series appears similar to other neuroprotection 
devices. The Claret CE Pro
TM
 and the Embrella (Edwards Lifesciences, Irvine, CA, USA) 
deflection system have been developed to lower the risk of cerebral embolism during the TAVR 
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procedure. Results of first-in-human experiences with these devices have demonstrated 
comparable technical success rates[38, 39]; however, the TriGard
TM
 EDD may offer superior 
protection against cerebral embolism due to its coverage of all three aortic arch vessels, 
compared with the Claret CE Pro
TM
 and Embrella devices, which lack coverage of the left 
subclavian artery. 
 
Other complications including vascular and bleeding complications are commensurate with rates 
seen in association with similar populations undergoing TAVR procedures, which range from 
11.0%[62]- 16.2%[1] for vascular complications and from 9.3%[62] - 16.8%[1] for bleeding 
complications and are not related to the TriGard
TM
. Acute kidney injury was reported in two 
subjects 10.5% (2/19), one reported as Stage 3 and one reported as Stage 1. While an embolic 
etiology cannot be excluded, these were likely related to contrast administration during the 
TAVR procedure; in both cases, no contrast was administered during positioning of the EDD so 
it is unlikely that use of the TriGard
TM
 device contributed. 
 
Lastly, the ability of the Keystone Heart EDD to maintain full 3-vessel coverage for the entire 
TAVR procedure correlates with anchorage of its upper stabilizer in the innominate artery and 
this angiographic marker can assist interventional cardiologists with device positioning. Proper 
patient selection and upper stabilizer anchoring at procedure initiation can ensure cerebral 





The DEFLECT study is a safety and feasibility study performed in a limited patient population 
intended for CE Marking.  The study is intended to continue enrollment to establish efficacy 
compared to historic controls. These early results provide the proof of concept to proceed to a 
larger prospective randomized clinical trial to establish the benefit of the EDD during the TAVR 
procedure compared with TAVR alone. 
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FIGURE REFERENCES AND LEGENDS 
 
 
Figure 1. Diffusion weighted-magnetic resonance images: (A) Baseline. (B) Following embolic 
event. Arrows indicate areas of restricted diffusion. 
 




Figure 3. Embrella embolic deflector. 
 
Figure 4. Keystone Heart Triguard
TM
 Embolic Deflection Device.  
 
Figure 5. Angiography demonstrating Keystone Heart Triguard
TM
 device position. (A) Before 
the TAVR procedure. White arrow indicates device upper stabilizer anchorage in innominate 
artery. (B) During the TAVR procedure. (C) After the TAVR procedure. TAVR, transcatheter 
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Table 2. Common neurocognitive tests used.  
Cognitive Domains Tests 
Attention SYNDROM-KURZTEST* 
TRAIL MAKING A*, †, ‡, §, | | 
ZIMMERMAN JOINT/DIVIDED ATTENTION TEST§, | | 
NUMBER/LETTER CANCELLATION*, #, * * 
SYMBOL DIGIT MODALITIES TEST† 
BELLS TEST# 
WAIS-R DIGIT SYMBOL‡, §, | |, * * 
LETTER-NUMBER SEQUENCING† 
Executive Function SYNDROM-KURZTEST INTERFERENCE LIST*, * * 
STROOP COLOR-WORD INTERFERENCE*, ‡ 
TRAIL MAKING B*, †, ‡, | |, # 
Language NAMING, READING# 
CONTROLLED ORAL ASSOCIATION‡ 
REGENSBURG WORD FLUENCY* * 
Visual Memory NONVERBAL LEARNING*, * *  
SYNDROM-KURZTEST PICTORIAL MEMORY*, * * 
REY-OSTERRIETH’S COMPLEX FIGURE TEST‡ 
TAYLOR’S COMPLEX FIGURE TEST‡ 
CORSI BLOCK-TAPPING TEST§, | | 
Verbal Memory VERBAL LEARNING MEMORY*, §, | |, * *  
REY AUDITORY VERBAL LEARNING†, ‡  
Psychomotor LINE TRACING* 
GROOVED PEGBOARD TEST†, ‡ 
Visual-constructive  WAIS BLOCK DESIGN*, ‡ 
HORN’S PERFORMANCE§, | | 
WAIS, Wechsler Adult Intelligence Scale; WAIS-R, WAIS Revised 
*Gerriets T, et al.[23] 
†Barber P, et al.[17] 
‡Lund C, et al.[18] 
§Knipp SC, et al.[22] 
| |Knipp SC, et al.[24] 
#Restrepo L, et al.[16] 
* *Schwarz N, et al.[19] 
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60 41 0.68 0.34 0.24 
Astarci 2011[54] 35 32 0.91 0.20 0.18 
Kahlert 2010[13] 32 27 0.84 0.18 0.16 
Ghanem 2010*[15] 22 16 0.73 0.13 0.09 
Arnold 2010[9] 25 17 0.68 0.14 0.10 
Total 174    0.76 
* Total study size was N=30.  N=22 subjects were imaged. DW-MRI, diffusion-weighted 
magnetic resonance imaging; TAVR, transcatheter aortic valve replacement. 
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Table 4. Baseline characteristics. 
Subject Characteristics 
DEFLECT 1 
(N = 20) 
Age (years) 82.4 ± 6.5 
Female   15 (75.0%) 
Current smoker (within the last year) 1 (5.3%) 
Ex- smoker   7 (36.8%) 
Non-insulin Dependent Diabetes Mellitus  2 (10.0%) 
Hypertension  15 (75.0%) 
Hyperlipidemia  10 (50.0%) 
Peripheral Vascular Disease  0 (0.0%) 
Prior CVA 1 (5.0%) 
Prior MI 3 (15.0%) 
COPD   3 (15.0%)  
Renal insufficiency  3 (15.0%)  
History of left ventricular dysfunction  6 (37.5%) 
History of angina pectoris  3 (15.0%)  
Current CCS functional classification at time of enrollment  
  Class I  18 (90.0%)  
  Class II  1 (5.0%)  
  Class III  1 (5.0%)  
  Class IV  0 (0.0%) 
Left ventricular ejection fraction (%) 58.8 ± 15.0 
Current NYHA class on enrollment admission  
  Class I  3 (15.0%)  
  Class II  4 (20.0%)  
  Class III  12 (60.0%)  
  Class IV  1 (5.0%)  
History of prior CABG  3 (15.0%)  
History of prior PCI 3 (15.0%)  
History of prior aortic valvular surgery  1 (5.0%)  
Values reported as mean ± SD or n(%). COPD, chronic obstructive pulmonary disease; CVA, 
cerebrovascular accident; TIA, transient ischemic attack. 
CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; NYHA, New 
York Heart Association; PCI, percutaneous coronary intervention. 
51 51 
Table 5. Device performance. 
Procedural Angiographic Analysis  
N = 20 






EDD Access to Aortic Arch  20 (100%) 
EDD is positioned in the aortic arch  20 (100%) 19 (95.0%) 15 (75.0%) 
EDD covers all 3 vessels (innominate, 
left common carotid, subclavian)  
19  (95.0%) 16 (80.0%) 13 (65.0%) 
EDD upper stabilizer is anchored in the 
innominate artery ostium  
17 (85.0%) 16 (80.0%) 12 (60.0%) 
Able to retrieve the final EDD and 
remove the delivery system intact  
20 (100%) 




Table 6. In-hospital and 30 day clinical endpoints. 
Clinical Endpoint Events 
In Hospital 






Primary safety endpoint: 




























Life-threatening (or disabling) 







Distal embolization (noncerebral) 
from a vascular source requiring 
surgery or resulting in amputation 








Major vascular or access-related 







Need for acute cardiovascular 
































Life threatening (or disabling) 







Acute kidney injury- Stage 3 
(including renal replacement 
therapy) % (n/N) 
5.0% (1/20) [0.0% - 24.9%] 5.0% (1/20) 
[0.0% - 
24.9%] 




Major vascular complication % 
(n/N) 
5.0% (1/20) [0.0% - 24.9%] 5.0% (1/20) 
[0.0% - 
24.9%] 
Repeat procedure for valve 
dysfunction % (n/N) 




















 Hemorrhagic stroke  0 .0% (0/20) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 









 Minor stroke disability  0.0% (0/20) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 








Transient ischemic attack  0.0% (1/20) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 
Encephalopathy  0.0% (0/20) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 
Bleeding Complications 









Intracranial hemorrhage  0 (0.0%) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 
Life threatening or disabling bleeding  0 (0.0%) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 
Minor bleeding  0 (0.0%) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 









Intracranial hemorrhage  0 (0.0%) 
[0.0% - 
16.8%] 
0.0% (0/20) [0.0%-16.8%] 
Values reported as n (%). CI, confidence interval; MACCE, major adverse cardiac and 
cerebrovascular events; MI, myocardial infarction. 
*There were a total of 2 clinical strokes. Both strokes were classified as major stroke disability. 




Table 7. Individual subject diffusion-weighted magnetic resonance imaging data. 








Proportion of patients 
with new ischemic 
lesions 
70% 76%[9, 13, 15, 45, 
53-55] 
-6% 
Maximum number of 
new lesions 
28 20[15, 45, 53] -- 
Mean number of new 
lesions  SD 
5.17.04 4.4[13, 15, 40, 45, 
53-55] 
-16% 




0.39 6.45[15, 45] -94% 
Mean single lesion 
volume  SD (cm
3
) 
0.120.13 0.34[13, 15, 45, 
54, 55] 
-65% 




3.94 70.3[15] -94% 
Mean total lesion 
volume  SD (cm
3
)  
0.700.98 1.64[13, 15, 45, 
54, 55] 
-57% 
*Average single lesion volume was calculated for each patient by dividing total lesion volume by 
the lesion number in each individual patient. DW-MRI, diffusion-weighted magnetic resonance 
imaging; SD, standard deviation. 
55 55 
Table 8. Basline demographic and procedural characteristics and successful device coverage. 




Age 82.4 ± 6.55 81.92 ± 7.02 83.29 ± 5.99 0.67 
Gender (female) 15 (75%) 10 (77%) 5 (71%) 0.79 
History of smoking 8 (42%)* 6 (46.2%) 2 (33.3%) 0.60 
History of diabetes 2 (10%) 1 (7.7%) 1 (14.3%) 0.22 
History of hypertension 15 (75%) 9 (69.2%) 6 (85.7%) 0.42 
History of hyperlipidemia 10 (50%) 8 (61.5%) 2 (28.6%) 0.16 
History of PAD/CAD 0 (0%) 0 (0%) 0 (0%) N/A 
Prior MI 3 (15%) 2 (15.4%) 1 (14.3%) 0.95 
History of LV 
Dysfunction 
6 (37.5%)* 4 (40%) 2 (33.3%) 0.79 
History of angina 3 (15%) 2 (15.4%) 1 (14.3%) 0.95 
LVEF (%) 58.8  15 56.91  15.39 63.00  14.83 0.67 
NYHA Class I 3 (15%) 1 (7.7%) 2 (28.6%) 0.45 
II 4 (20%) 4 (30.8%) 0 (0%) 
III 12 (60%) 7 (53.9%) 5 (71.4%) 
IV 1 (5%) 1 (7.7%) 0 (0%) 
Prior CABG 3 (15%) 2 (15.4%) 1 (14.3%) 0.95 
Prior PCI 3 (15%) 3 (23.1%) 0 (0%) 0.17 
Prior aortic valve surgery 1 (5%) 0 (0%) 1 (14.3%) 0.14 
Aortic arch 
classification 
Type I 7 (35%) 5 (38.4%) 2 (28.6%) 0.70 
Type 
II 
9 (45%) 5 (38.4%) 4 (57.1%) 
Type 
III 
4 (20%) 2 (15.4%) 2 (28.6%) 
Innominate artery RVD 11.49  1.54 11.35  1.63 11.76  1.43 0.58 
EDD upper stabilizer 
maintained anchorage in 
innominate artery 
12 (60%) 12 (92.3%) 0 (0%) P < 0.0001 
EDD lower stabilizer in 
position 




Medtronic 10 (50%) 6 (46.2%) 4 (57.1%) 0.64 
Edwards 10 (50%) 7 (53.8%) 3 (42.9%) 
Ostial stenosis innominate 
artery 
1 (5%) 1 (7.7%) 0 (0%) 1.00 
Take off angle from 
innominate artery and 
aortic arch 
73.5 ± 26.2 71.23 ± 29.28 77.56 ± 20.61 0.61 
Take off angle from EDD 
after positioning 
114.7 ± 30.4* 112.5 ± 33.83 119.5 ± 95.42 0.65 
Take off angle from EDD 120.3 ± 27.0* 120.3 ± 27.0 N/A N/A 
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after TAVR  
Calcification ascending 
aorta 





Mild 4 (20%) 2 (15.4%) 2 (28.6%) 0.35 
Moderate 3 (15%) 2 (15.4%) 1 (14.3%) 
Severe 0 (0%) 0 (0%) 0 (0%) 
Calcification in aortic 
arch 






Proximal 8 (40%) 6 (46.2%) 2 (28.6%) 0.89 
Mid 7 (35%) 4 (30.8%) 3 (42.9%) 





Mild 4 (20%) 2 (15.4%) 2 (28.6%) 0.24 
Moderate 10 (50%) 7 (53.9%) 3 (42.9%) 
Severe 1 (5%) 1 (7.7%) 0 (0%) 
*indicates missing values. CABG, coronary artery bypass grafting; CAD, coronary artery 
disease; EDD, embolic deflection device; LV, left ventricular; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral 
artery disease; PCI, percutaneous coronary intervention; RVD, reference vessel diameter; 
TAVR, transcatheter aortic valve replacement. 
 
